Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice

Vaccine

Volumn 30, Issue 36, 2012, Pages 5310-5315

  Chen, Jiansen ^a   Lin, Miaoduan ^a   Li, Neng ^a   Lin, Liping ^a   She, Feifei ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Attenuated Salmonella typhimurium; Codon optimization; Helicobacter pylori; Outer inflammatory protein; Vaccine

Indexed keywords

BACTERIAL PROTEIN; DNA VACCINE; OIPA PROTEIN; OUTER INFLAMMATORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CODON; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; GENE CONSTRUCT; GENE SEQUENCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; SALMONELLA; VACCINATION; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CODON; CYTOKINES; FEMALE; GENE EXPRESSION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICE; MICE, INBRED C57BL; SALMONELLA TYPHIMURIUM; VACCINES, DNA;

EID: 84864011949     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.052     Document Type: Article

References (38)

1. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010, 7(11):629-641.
2. Selgrad M., Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011, 27(6):565-570.
3. Flach C.-F., Svensson N., Blomquist M., Ekman A., Raghavan S., Holmgren J. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 2011, 29(6):1235-1241.
4. Summerton N.A., Welch R.W., Bondoc L., Yang H.H., Pleune B., Ramachandran N., et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28(5):1404-1411.
5. Zhou W.Y., Shi Y., Wu C., Zhang W.J., Mao X.H., Guo G., et al. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 2009, 27(36):5013-5019.
6. Panthel K., Jechlinger W., Matis A., Rohde M., Szostak M., Lubitz W., et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003, 71(1):109-116.
7. Keenan J., Oliaro J., Domigan N., Potter H., Aitken G., Allardyce R., et al. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun 2000, 68(6):3337-3343.
8. Lee A., Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994, 62(8):3594-3597.
9. Ingolotti M., Kawalekar O., Shedlock D.J., Muthumani K., Weiner D.B. DNA vaccines for targeting bacterial infections. Expert Rev Vaccines 2010, 9(7):747-763.
10. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998, 72(2):1497-1503.
11. Vinner L., Nielsen H.V., Bryder K., Corbet S., Nielsen C., Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine 1999, 17(17):2166-2175.
12. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001, 75(22):10991-11001.
13. Metzger W.G., Mansouri E., Kronawitter M., Diescher S., Soerensen M., Hurwitz R., et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004, 22(17-18):2273-2277.
14. Koesling J., Lucas B., Develioglou L., Aebischer T., Meyer T.F. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001, 20(3-4):413-420.
15. Shata M.T., Reitz M.S., DeVico A.L., Lewis G.K., Mucosal Hone D.M. systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001, 20(3-4):623-629.
16. Gahan M.E., Webster D.E., Wijburg O.L., Wesselingh S.L., Strugnell R.A. Impact of prior immunological exposure on vaccine delivery by Salmonella enterica serovar typhimurium. Vaccine 2008, 26(49):6212-6220.
17. Michael A., Stratford R., Khan S., Dalgleish A., Pandha H. Novel strains of Salmonella typhimurium as potential vectors for gene delivery. FEMS Microbiol Lett 2004, 238(2):345-351.
18. Wang Q.L., Pan Q., Ma Y., Wang K., Sun P., Liu S., et al. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine 2009, 27(48):6712-6722.
19. Chen J., Lin L., Li N., She F. Enhancement of Helicobacter pylori outer inflammatory protein DNA vaccine efficacy by co-delivery of interleukin-2 and B subunit heat-labile toxin gene encoded plasmids. Microbiol Immunol 2012, 56(2):85-92.
20. Ko H.J., Ko S.Y., Kim Y.J., Lee E.G., Cho S.N., Kang C.Y. Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun 2005, 73(9):5666-5674.
21. Rush C., Mitchell T., Garside P. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J Immunol 2002, 169(9):4951-4960.
22. Rodriguez F., Harkins S., Redwine J.M., de Pereda J.M., Whitton J.L. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol 2001, 75(21):10421-10430.
23. Miki K., Nagata T., Tanaka T., Kim Y.H., Uchijima M., Ohara N., et al. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect Immun 2004, 72(4):2014-2021.
24. Foster H., Sharp P.S., Athanasopoulos T., Trollet C., Graham I.R., Foster K., et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 2008, 16(11):1825-1832.
25. Abdulhaqq S.A., Weiner D.B. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008, 42(1-3):219-232.
26. Yan J., Corbitt N., Pankhong P., Shin T., Khan A., Sardesai N.Y., et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011, 29(41):7173-7181.
27. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Chung C.W., Sako E., et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008, 26(40):5128-5134.
28. Bennicelli J., Wright J.F., Komaromy A., Jacobs J.B., Hauck B., Zelenaia O., et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008, 16(3):458-465.
29. Radcliffe P.A., Sion C.J.M., Wilkes F.J., Custard E.J., Beard G.L., Kingsman S.M., et al. Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Ther 2007, 15(4):289-297.
30. Liu K.Y., Shi Y., Luo P., Yu S., Chen L., Zhao Z., et al. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine 2011, 29(38):6679-6685.
31. Liljebjelke K.A., Petkov D.I., Kapczynski D.R. Mucosal vaccination with a codon-optimized hemagglutinin gene expressed by attenuated Salmonella elicits a protective immune response in chickens against highly pathogenic avian influenza. Vaccine 2010, 28(27):4430-4437.
32. Hall L.J., Clare S., Pickard D., Clark S.O., Kelly D.L.F., Ghany M.A.E., et al. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine 2009, 27(49):6894-6904.
33. Hegazy W.A.H., Hensel M. Salmonella enterica as a vaccine carrier. Future Microbiol 2011, 7(1):111-127.
34. Hopkins S.A., Niedergang F., Corthesy-Theulaz I.E., Kraehenbuhl J.-P. A recombinant Salmonella typhimurium vaccine strain is taken up and survives within murine Peyer's patch dendritic cells. Cell Microbiol 2000, 2(1):59-68.
35. Gottwein J.M., Blanchard T.G., Targoni O.S., Eisenberg J.C., Zagorski B.M., Redline R.W., et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis 2001, 184(3):308-314.
36. Taylor J.M., Ziman M.E., Canfield D.R., Vajdy M., Solnick J.V. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 2008, 44(1):20-27.
37. Taylor J.M., Ziman M.E., Huff J.L., Moroski N.M., Vajdy M., Solnick J.V. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 2006, 24(23):4987-4994.
38. Blanchard T.G., Eisenberg J.C., Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 2004, 22(7):888-897.